Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Merck & Co. Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Loans payable and current portion of long-term debt 1,372 1,946 2,412 6,431 3,610
Trade accounts payable 3,922 4,264 4,609 4,594 3,738
Accrued and other current liabilities 15,766 14,159 13,859 13,053 12,549
Income taxes payable 2,649 1,986 1,224 1,575 736
Dividends payable 1,985 1,884 1,768 1,674 1,587
Current liabilities 25,694 24,239 23,872 27,327 22,220
Long-term debt, excluding current portion 33,683 28,745 30,690 25,360 22,736
Deferred income taxes 871 1,795 3,441 1,015 1,470
Other noncurrent liabilities 8,792 8,323 9,434 12,482 11,970
Noncurrent liabilities 43,346 38,863 43,565 38,857 36,176
Total liabilities 69,040 63,102 67,437 66,184 58,396
Common stock, $0.50 par value 1,788 1,788 1,788 1,788 1,788
Other paid-in capital 44,509 44,379 44,238 39,588 39,660
Retained earnings 53,895 61,081 53,696 47,362 46,602
Accumulated other comprehensive loss (5,161) (4,768) (4,429) (6,634) (6,193)
Treasury stock, at cost (57,450) (56,489) (57,109) (56,787) (55,950)
Total Merck & Co., Inc. stockholders’ equity 37,581 45,991 38,184 25,317 25,907
Noncontrolling interests 54 67 73 87 94
Total equity 37,635 46,058 38,257 25,404 26,001
Total liabilities and equity 106,675 109,160 105,694 91,588 84,397

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Merck & Co. Inc. current liabilities increased from 2021 to 2022 and from 2022 to 2023.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Merck & Co. Inc. noncurrent liabilities decreased from 2021 to 2022 but then increased from 2022 to 2023 not reaching 2021 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Merck & Co. Inc. total liabilities decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Total Merck & Co., Inc. stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Merck & Co. Inc. total Merck & Co., Inc. stockholders’ equity increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.